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Abstract
Maternal vulnerability to adversity has long-term impact on the developing 
child. About 20% of the pregnant women suffer from affective disorders. Fetal 
exposure to maternal adversity may lead to detrimental consequences later in 
life. Maternal affective disorders are increasingly treated with antidepressants, 
especially selective serotonin reuptake inhibitors (SSRIs). However, the long-term 
consequences for the offspring after exposure to this medication are unclear. The 
interplay between maternal adversity and SSRI treatment has been under inves-
tigation and here we discuss how maternal adversity and SSRIs are able to shape 
offspring development. Specifically, we will discuss animal models addressing 
behavioral outcomes to understand how the prenatal environment influences the 
health of the developing child across the life span.
Keywords: maternal vulnerability, maternal depression, selective serotonin reuptake 
inhibitors, antidepressants, pregnancy, neurodevelopment
1. Introduction
Although pregnancy is often portrayed as a time of great joy, that is not the reality 
for all women. Depressive symptoms during pregnancy are not uncommon; in fact, 
20% of women experience some depressive symptoms during any time of their 
pregnancy [1]. The number of women who suffer from major depression during 
pregnancy is estimated to be 4–8% [2, 3]. According to the DSM-5, this disorder is 
characterized by a depressed mood or loss of interest or pleasure in daily activities for 
more than 2 weeks. Depression is accompanied by impaired social, occupational, and 
educational functioning. Untreated antenatal depression, that is to say a depressive 
episode during pregnancy, may have a tremendous effect on the developing child [4].
Maternal vulnerabilities during pregnancy, such as depression, anxiety, or high 
stress levels due to other reasons, are associated with increased and continued 
activation of the hypothalamic-pituitary-adrenal (HPA) axis. The continued activa-
tion of the HPA axis in depressed patients causes an elevated stress response and 
increased cortisol levels [5]. About 40% of the cortisol passes through the placenta 
[6]. Consequently, increased cortisol levels are found in the urine and saliva of the 
infants of depressed mothers [7].
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Fetal exposure to increased maternal stress levels impacts the developing child. 
For example, high levels of maternal cortisol are associated with reduced neurologi-
cal development [8] and altered cortisol responses of the unborn child to a stressor 
[9]. Furthermore, maternal vulnerabilities such as anxiety, depression, and elevated 
stress levels are associated with the increased fearful temperament and negative 
behavioral reactivity to novelty in infants [9, 10], and delayed cognitive and neuro-
motor development [11, 12] that persists into adolescence [13]. In addition, antenatal 
depression has also been linked with disturbed sleep patterns in infants [14] and in 18 
and 30 months old children [15]. Furthermore, antenatal depression has been linked 
to reduced fetal growth [16, 17] and altered cardiovascular responses to stress [18].
Several studies have looked into the effects of maternal vulnerability on the 
behavioral development of the child. For example, maternal anxiety, but not ante-
natal depression is linked to a difficult child temperament at the age of 4–6 months 
[19], an increase in behavioral and emotional problems at the age of 4 [20] and 
more internalizing behavior at the age of 8 [21]. Moreover, antenatal depression is 
associated with delayed development in 18-month-olds [22], increased external-
izing behaviors and a slight decrease in IQ in 8-year-old children [21], and violent 
behavior during adolescence [23]. On the long-term prenatal exposure to maternal 
depression is associated with a higher chance of developing depression during ado-
lescence [24, 25] and adulthood [26], or risk of developing other psychopathologies 
[27]. Maternal anxiety as well as maternal depression during pregnancy is correlated 
with child attention problems at the age of 3 and 4 [28]. Moreover, an increase in 
reporting symptoms of antenatal depression and anxiety positively correlated with 
an increase in internalizing behaviors in 4-year-olds [29]. So anxiety and depression 
appear to have similar but, at the same time, different effects on offspring develop-
ment; however, it is difficult to discern between maternal anxiety and depression, 
due to common comorbidity between these mental health conditions [30].
Overall, maternal vulnerability, such as depression and anxiety, during preg-
nancy can negatively influence the unborn child on both physiological and behav-
ioral levels. However, it remains difficult to discern the direct effects of antenatal 
depression (an aversive postnatal environment due to a depressed mother), and 
genetic predisposition to vulnerability on fetal and infant development. In addition, 
an increasing percentage of women suffering from depression and/or anxiety are 
treated with antidepressants, which on itself might have tremendous effects on the 
developing child.
2. Maternal SSRI treatment and offspring development
Pharmacological treatment of antenatal depression and/or anxiety is sometimes 
unavoidable. The treatment with antidepressants may relieve the symptoms of 
the depression of the mother and could help in reducing the impact on the unborn 
child. Nowadays, a considerable number of women are treated with antidepressants 
during pregnancy. In Europe, this concerns 2–3% of the pregnant women [16, 31], 
while in the U.S., the occurrence is as high as up to 13% [32, 33]. The most pre-
scribed antidepressants are selective serotonin reuptake inhibitors (SSRIs), because 
of their good efficacy, few side effects, and therapeutic safety [34]. These drugs 
work by blocking the serotonin transporter and hereby preventing the reabsorption 
of the neurotransmitter serotonin into the presynaptic nerve cell. Subsequently, 
extracellular serotonin levels in the synaptic cleft are increased and more serotonin 
is available to bind the postsynaptic receptors. Although, SSRIs are considered safe 
for antenatal use [35], it has been reported that the use of SSRIs during pregnancy 
may negatively influence the development of the unborn child. SSRIs can cross the 
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placenta and are found in the amniotic fluid [36, 37], affecting therefore not only 
the mother but also the developing child. This is of extra concern as serotonin plays 
a key role in embryonal development. During the development of the fetal brain, 
serotonin acts as a neurotrophic factor, regulating cell division, differentiation, 
migration, growth cone elongation, dendritic pruning, myelination, and synapto-
genesis [38]. In fact, serotonin receptors and serotonergic metabolic enzymes are 
expressed before serotonin-producing neurons are present in the brain [39]. Thus, 
changes in the serotonin levels during neurodevelopment, for instance, by the 
administration of SSRIs during pregnancy, potentially affect a number of processes 
in the offspring.
Indeed, literature shows a number of side effects in the offspring due to prenatal 
SSRI exposure. First of all, SSRI exposure during pregnancy has been associated 
with attenuated basal cortisol levels in neonates [40, 41], and differential cortisol 
levels in 3-month-old infants in response to a stressor [42]. Also, the neonatal heart 
rate response to an acute noxious event is attenuated [43]. Furthermore, several 
behavioral changes have been reported, such as increased internalizing behaviors, 
such as depression, anxiety, and social withdrawal during childhood [44, 45], 
increased externalizing behaviors in 4-year-old children [46], and disrupted sleep 
patterns in newborn [47]. In addition, SSRIs reduce utero-placental blood flow, a 
mechanism thought to be involved with hypertension in preeclampsia and gesta-
tional diabetes [48, 49].
Recently, there has been much interest in the link between antenatal SSRI 
treatment and the development of autism spectrum disorders (ASDs) in the 
child. ASD is a neurodevelopmental condition characterized by difficulties in 
social communication and unusually restricted, repetitive behavior and inter-
ests. The available literature shows an association between the prenatal use of 
SSRIs and the increased risk of ASDs in the child [50–54]. It is theorized that 
this is facilitated by an increase in serotonergic activity during brain develop-
ment [55]. Several studies found abnormal placental histology to be associated 
with autism diagnosis [56, 57]. Moreover, autistic patients have elevated blood 
platelet serotonin levels [58, 59]. Taken together, these results imply the seroto-
nergic influences on maternal-fetal interaction, although the exact mechanisms 
remain elusive.
A possible route for passing adverse intra-uterine effects to the fetus is via 
epigenetic regulation. For example, increased maternal depressive mood during 
pregnancy is associated with reduced methylation of the promotor of the gene 
coding the serotonin transporter (SERT) in both mothers and newborns [60]. These 
results suggest increased SERT mRNA levels and subsequently modified serotonin 
levels, contributing to increased vulnerability later in life [61]. St-Pierre and col-
leagues therefore conclude that all parameters that can alter serotonin homeostasis 
during early development could lead to structural and functional changes in fetal 
development and brain circuits [62], which could subsequently result in a predispo-
sition to psychopathology in adulthood.
Thus, several studies have shown an increased risk for developing the child 
both during antenatal depression and after prenatal SSRI exposure. However, it is 
difficult to discern between the effects of the SSRIs and the effects of the depres-
sion itself, as healthy mothers do not administer antidepressants. For example, 
meta-analyses show that the risk found for ASD in the offspring after prenatal SSRI 
exposure is decreased after correcting for maternal mental illness [63]. Thus, the 
effects of SSRIs mentioned could be solely due to the administration of the SSRIs, 
or alternatively, the SSRIs are only partially effective and therefore do not eliminate 
all the adverse effects of the depression, thereby adding up to the adverse effects of 
antenatal depression [4].
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3. Preclinical studies: perinatal SSRI exposure
In humans, it is difficult, if not impossible, to discern the effects of the SSRI and 
the depression itself on fetal development. It is not ethical to study the effects of 
SSRIs in healthy pregnant women. In addition, it is impossible to study gene expres-
sion and epigenetic changes in the fetal brain as a result of prenatal SSRI exposure. 
Due to these limitations of human research, researchers often use animal models, 
specifically rodents, to get a more profound insight into the mechanisms underlying 
the observations seen in human studies.
It should be noted that the timing of brain development is different in humans 
compared to rodents. A rodent brain at postnatal day 7–10 is considered to be the 
rough equivalent of a newborn human infant [64]. Thus, to mimic SSRI exposure 
during the entire pregnancy in humans, rodents should be exposed both pre- and 
postnatally. In addition, it is known that SSRIs are also found in breast milk [65], 
again underlining the need to research both the effects of pre- and postnatal SSRI 
exposure. For exposure to SSRIs around these time points, we will use the term peri-
natal SSRI exposure; when timing of the SSRI exposure is of particular importance, 
we will distinguish between pre- and postnatal exposure to SSRIs.
3.1 Social behavior
As serotonin is a key regulator of social responses and prenatal SSRI exposure is 
being linked to ASDs, which are characterized by impaired social behavior [54], this 
behavioral parameter is often addressed in researching the effects of prenatal SSRI 
exposure in animals.
Social play at juvenile age is an essential behavior in rodents for the development 
of the necessary social, cognitive, emotional, and physical skills [66]. SSRIs are well 
described in literature as reducing social play behavior in young rats when prenatally 
[67] or postnatally [68–71] administered. These effects of SSRIs seem sex-mediated, as 
males are more affected than females [70], or females are not even affected at all [71]. 
This is interesting because this is analogous to the situation, where men are 3–4 times 
more likely to get diagnosed with ASDs compared to women [72]. In spite of that, not 
all studies found similar results. In a recent study [73], social play behavior was unal-
tered after prenatal SSRI exposure. However, in the latter study, social play was assessed 
with a familiar play partner (littermate), while other studies use a novel conspecific.
Findings on the effects of prenatal SSRI exposure on social behavior at adult age 
are more conflicting. Olivier and colleagues [67] found reduced social exploration in 
adult male rats after prenatal SSRI exposure. While another study found that 4 days of 
postnatal treatment with SSRIs led to increased sniffing, contact with, and total social 
interaction with a novel conspecific in males [74]. On top of that, other studies found 
no effect of prenatal SSRI exposure on social exploration in both males and females 
[75, 76]. In general, studies on the exposure of SSRIs during early development on 
adult social interaction are unconvincing. Studies on social motivation on the other 
hand, measured as the preference of a rodent to spend time with a novel conspecific 
over interaction with an object, appear to be more in line. Decreased social motivation 
is found in both males and females, when postnatally exposed to SSRIs [69–71, 77]. On 
the other hand, prenatal exposure to SSRIs led to an increase in motivation to interact 
with a conspecific in mice [75]. Thus, while literature on the effects of perinatal SSRI 
exposure on social behavior during adult is still limited, both timing of the exposure 
and sex are important factors in the subsequent social development.
Another form of social interaction under the influence of the neurotransmitter 
serotonin is aggression [78]. Indeed, during both childhood and adulthood, SSRIs are 
successfully used to reduce aggressive and violent behavior in certain mental disorders 
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[79, 80]. Perinatal exposure to SSRIs, on the other hand, leads to increased external-
izing behavior, such as aggression, in children [46]. In rodents, the effects of perinatal 
SSRI exposure on aggressive behavior are conflicting. Several studies show an increase 
in male, but not female aggressive behavior [73, 75, 76, 81], while other studies show 
reduced aggressive behavior in male rodents perinatally exposed to SSRIs [82, 83].
Serotonin is known to be involved in the regulation of maternal care [84]. Thus, 
perinatal SSRI exposure can be expected to alter maternal caregiving behavior of 
both the SSRI-treated mother and her female offspring, when they are mothers 
later in life. Typical maternal behaviors include nest building, gathering the young 
into the nest, maternal licking, and nursing the pups. Studies on the effect of direct 
SSRI exposure found an increase in these behaviors [85, 86], or no effect at all [87]. 
So far, only one study has been performed on the effects of prenatal exposure on 
maternal care later in life, and interestingly here, they found a reduction in maternal 
caregiving behaviors [75]. This suggests that direct changes in serotonin levels, such 
as an increase in extracellular serotonin levels during SSRI treatment and changes in 
serotonin levels during development differentially alter the quality of maternal care.
Another role for serotonin is its signaling in sexual development, on both the 
brain and at a behavioral level [88]. In addition, chronic SSRI treatment may result 
in sexual dysfunction [89]. Not much is known on the effect of perinatal SSRI expo-
sure on the sexual behavior of these children later in life; however, several studies 
have been performed in rodents. The effect of perinatal SSRI exposure depends 
on the timing of treatment. When postnatally administered, male sexual behavior 
later in life is reduced [70, 90–93]. In contrast when the SSRI is prenatally, or both 
prenatally and postnatally, administered, there is no effect on sexual behavior of 
male rodents [94, 95]. Interestingly, there appears to be an opposite effect in female 
offspring, where postnatal SSRI exposure leads to an increase in sexual behaviors 
[75, 96]. Thus, apart from the effect of timing, sex of the offspring also differen-
tially alters the effect of perinatal SSRI exposure on reproductive behavior.
3.2 Affective behavior
It has long been established that serotonin is involved in affective disorders [97]. 
Affective disorders, also called mood disorders, include psychiatric disorders such 
as major depressive disorder and anxiety disorders.
A large body of preclinical research has shown the relationship between perinatal 
SSRI exposure and anxiety. Although there are some studies finding no effects, several 
studies did find an increase in anxiety-like behavior and/or less explorative behavior in 
an open field test, when rodents are perinatally exposed to SSRIs [67, 83, 98–104]. An 
increase in anxiety-like behavior in the elevated plus maze and the novelty-suppressed 
feeding test are also found [67, 98, 99, 105]. Nevertheless, there are also studies that 
did not find effects at all [87, 91, 106–111], and two studies even found a decrease in 
behaviors related to anxiety [92, 112]. Even though results differ among studies, these 
differences are not clearly linked to sex of the offspring or timing of the SSRI expo-
sure. So even though there appears to be a clear link between perinatal SSRI exposure 
and anxiety later in life, to get a more profound insight into the mechanisms behind 
this and the role of timing and sex, more researches have to be done.
It is difficult to determine if a rodent is depressed, moreover, to determine if it 
is even possible for rodents to experience depression. However, rodents can show 
behavior characteristics of the behaviors, and humans show during episodes of 
major depression. Such behaviors encompass despair and anhedonia [113]. To 
measure behavioral despair in rodents, the forced swim test is usually performed 
[114]. In this test, the animal is placed in an unescapable container filled with 
water, forcing the rodent to swim. After making efforts to escape the animal may 
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eventually stop his efforts and become immobile. The amount of time spent immo-
bile is used as a measure of helplessness and behavioral despair. As reviewed [115], 
many, but not all, studies performing the forced swim test after perinatal SSRI 
exposure found an increase in immobility [83, 99, 100, 105, 106, 109, 110, 116–121]. 
Three studies did not find an effect [67, 87, 111], and three studies even found a 
decrease in immobility [103, 112, 122]. The reviewers propose that these differences 
may be due to strain effects, some strains could be more susceptible to early life 
SSRI exposure, while others are resistant. In addition, they point out that the effect 
of perinatal SSRI exposure is greater, when the animals are exposed during early 
postnatal period rather than the prenatal period.
Anhedonia is another behavior often assessed as a measure for depression. 
Anhedonia is the inability or lack of motivation to experience pleasure from 
rewarding activities and is measured in rodents with the sucrose preference test 
[123]. In this test, two drinking bottles are placed in the rodent’s home cage. One is 
filled with water and the other with a sucrose solution. Preference for the sucrose 
solution is considered as the typical hedonic behavior, and lack of bias toward the 
sucrose water is characterized as a sign of anhedonia. It appears that only postna-
tal SSRI exposure increases anhedonia later in life [124], as opposed to prenatal 
exposure [67, 125]. This once more emphasizes that the moment of exposure is an 
important factor in assessing the effects of perinatal SSRI exposure.
Thus, not only sex of the offspring, but also the timing of the SSRI exposure 
appears to play an important role in behavioral development. However, all aforemen-
tioned studies are performed in offspring from healthy mothers. In practice, pregnant 
women are usually treated with SSRIs when they are suffering from anxiety and/or 
depression. It is likely that both maternal factors and the treatment with SSRIs affect 
serotonin functioning in the embryo and infant. The interplay of these two factors 
might shape the development of the fetus in a different way than antenatal depression 
or prenatal SSRI exposure on its own. Thus, to make a more valid translational step to 
the human situation, animal models of maternal vulnerability have to be used.
4.  Preclinical studies: maternal vulnerability and perinatal SSRI 
exposure
To induce maternal vulnerability in healthy rodents, researchers often use the 
early life stress model (ELS). Maternal separation is one of the manipulations often 
used to create ELS; in this procedure, the offspring is taken away from the mother 
for few hours during the day, and this happens daily during a period of few early 
postnatal weeks. This procedure leads to a long-term and intergenerational increase 
in anxiety and depressive-like behaviors [126–131]. Female offspring exposed to 
ELS and showing an increase in anxiety and depressive-live behaviors can be used 
as a model of maternal vulnerability later in life. Little is known about the interac-
tion of such maternal vulnerability and treatment with SSRIs during pregnancy.
4.1 Social behavior
So far, only two studies have been looking into the combined effects of maternal 
vulnerability and perinatal SSRI exposure on social play behavior and social inter-
action of the offspring later in life. In 2017, Gemmel and colleagues [73] showed 
that the reduction in social play behavior in juveniles due to maternal vulnerability 
is prevented by perinatal SSRI treatment regardless of the sex of the offspring. This 
suggests a rescuing effect of SSRIs on social behavior in offspring of stressed moth-
ers. However, social aggressive play was increased in adolescent offspring exposed 
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to perinatal fluoxetine and maternal vulnerability in both sexes. In addition, time 
grooming a novel conspecific was decreased in males only. In a later study, Gemmel 
and colleagues [132] did not find such an interaction effect on social behavior in 
adult offspring. Even though, maternal vulnerability itself decreased social inves-
tigation in adult males while perinatal SSRI exposure increased social investigation 
in adult females and increased social play in adult males. Thus, normalization, by 
SSRIs, of altered social play and social interaction, due to maternal vulnerability 
might only be short-lived as it does not persist into adulthood. With regard to 
aggression, however, long-term protective effects of SSRIs are found [81]. In this 
study, aggressive behavior was decreased as a result of maternal vulnerability, 
which was normalized when perinatal SSRI exposure was included in the treatment.
One study has looked into the combined effect of SSRI exposure and maternal 
vulnerability on offspring sexual development [133]. Perinatal SSRI exposure 
reduced sexual behavior in male offspring, while interestingly maternal vulnerabil-
ity alone or the combination of maternal vulnerability and perinatal SSRI exposure 
did not have any effect on the development of sexual behavior.
So, even though SSRI treatment of vulnerable mothers appears to have protec-
tive effects on offspring social development, these findings are not consistent over 
all types of behavior and differ with the moment of assessment of the offspring.
4.2 Affective behavior
Affective behaviors of the offspring such as anxiety and depression-like behaviors 
have also been studied after the offspring was exposed to a combination of maternal 
vulnerability and perinatal SSRI exposure. One study [134] shows that the increase 
in anxiety due to maternal vulnerability can be reversed by the postnatal administra-
tion of SSRIs. When prenatally administered, such a rescuing effect is not found 
[87]; however, the effect of maternal vulnerability was limited and was only found 
in males in this study. Two studies assessed depressive-like behavior after perinatal 
exposure to both maternal vulnerability and SSRIs. Both studies found that SSRIs 
normalize the increase in immobility in the forced swim test due to maternal vulner-
ability [87, 135]. Thus so far, the effect maternal vulnerability has on anxiety and 
depressive-like symptoms in the offspring later in life appear to be reversed by SSRIs.
5. Conclusion
Thus, children from mothers who suffer from anxiety or major depression 
during their pregnancy are at risk of developing several psychopathologies later in 
life. Moreover, treatment with SSRIs during pregnancy can also lead to long-term 
consequences for the children. However, it is difficult to determine if these effects 
are due to the SSRI treatment, maternal vulnerability, or a combination of both. 
Preclinical research in rodents shows that perinatal SSRI exposure on itself leads 
to alterations in social behavior later in life. Specifically, social play in juveniles, 
sexual behavior, maternal care in females, and aggression in males are influenced. 
Affective behaviors are also influenced, and both anxiety and depressive-like 
behaviors are increased due to perinatal SSRI exposure. Both the moments of SSRI 
exposure, pre- or postnatal, and sex of the offspring appear to be important factors 
in the development of social and affective behaviors after perinatal SSRI treatment.
Recently, researchers have started to look into the combined effects of maternal 
vulnerability and perinatal SSRI exposure in preclinical studies to make a more 
valid translational step to the human situation. Even though only a few studies have 
been done so far, it seems that, at least some, developmental alterations on offspring 
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behavior due to maternal vulnerability can be normalized by perinatal SSRI expo-
sure. These are interesting and promising results and further investigation into the 
risks and benefits of SSRI use during pregnancy in appropriate animal models are 
necessary to help depressed women in their decision to use SSRIs during pregnancy.
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